Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22062862 | 0.78 | PDE10A (0.49) | PDE10ATAAR1 | |
| SCHEMBL19028071 | 0.71 | GAA (0.32) | — | |
| SCHEMBL29975682 | 0.71 | GAA (0.32) | — | |
| SCHEMBL21355574 | 0.71 | TAAR1 (0.38) | PDE10ATAAR1 | |
| SCHEMBL31314110 | 0.71 | TDP1 (0.35) | PDE10ATAAR1 | |
| SCHEMBL17236176 | 0.70 | PDE10A (0.37) | PDE10ATAAR1 | |
| SCHEMBL31093821 | 0.70 | HRH4 (0.35) | PDE10A | |
| SCHEMBL31353073 | 0.69 | TAAR1 (0.37) | TAAR1 | |
| Hydrochloric Acid SCHEMBL17225047 | 0.69 | PDE10A (0.36) | PDE10ATAAR1 | |
| SCHEMBL21223482 | 0.68 | NOS3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| CN-118084870-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084867-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084866-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084868-A | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112105419-B | Condensed ring compound | 豪夫迈·罗氏有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230089126-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236068-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20210230142-A9 | FUSED RING COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-29 | — | — | US | disclosed |
| CN-112105419-A | Fused ring compound | 豪夫迈·罗氏有限公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3735299-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230142-A9 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885 |
| US-20230089126-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885 |
| US-12084429-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885 |
| US-11236068-B2 | Fused ring compounds | KRAS, NRAS, HRAS | PDE10A 4280/4885TAAR1 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.